

Index

a

- Abelson tyrosine kinase inhibitors (Abl)
43, 94, 144, 184
- acetylcholine binding protein (AChBP)
166, 167
- O*-acetylcyanohydrins 296
- acid/base extraction 126
- active angiotensin II receptor blocker
246
- active fluidic control 164
- active pharmaceutical ingredients (APIs)
1, 67, 73–75, 105, 199, 227,
233–263, 269–304, 311, 322
- active reactor 2
- C*-acylation of, vinylogous amide 200,
212
- adamantanecarboxylic acid 275
- additive-free *N*-Boc deprotection 11
- advanced technologies, multistep flow
synthesis 255–262
- modular flow system 260–261
- PAT 256, 258
- self-optimization 256–260
- sensors and in-line analysis 255
- toward full automation 261–262
- Advion miniature mass spectrometer
(MS) 37, 39, 55, 69, 109, 163, 164,
256
- alcohol dehydrogenase (ADH) 297, 298
- aldehyde oxidation 303
- Aldol condensation 219, 288
- 3-alkoxy-substituted acetophenone imines
275
- alkyl organozinc reagents 83
- allylboronic ester 281
- amidation of, methyl nicotinate 57
- amide bond formation 70, 105, 107–109,
113, 118, 140
- amino acid pool 186
- aminobenzoxazole 5
- 9-amino(9-deoxy)epi cinchona alkaloids
284
- aminoindazolines 72
- 1-amino-4-methylpiperazine 204
- 2-aminopyrimidine derivative 132, 207
- 2-aminoquinazolines 73
- angiotensin-converting-enzyme (ACE)
inhibitors 44, 313
- anion-exchange resin 318–322, 325
- anti-bacterial agents
- Cefotaxime 202–203
- Ciprofloxacin 200–201
- Linezolid 201–202
- Rifampicin 203–205
- anti-cancer agents
- Imatinib 205–207
- Lomustine 205
- anti-fungal agents
- Fluconazole 207–210
- Flucytosine 210
- anti-HIV agents
- (*R*)-propylene carbonate
210–211, 212
- Dolutegravir 211–214
- Efavirenz 215–217
- Lamivudine 214–215

- anti-malarial agent
 - hydroxychloroquine 221–222
 - anti-psychotic drug chlorpromazine 123
 - aqueous-based solvents 39
 - Arabidopsis thaliana* (AtHNL) 296
 - artificial intelligence (AI) 44, 51, 93, 160, 255
 - based learning procedures 51
 - β -arylated carbonyl compounds 293
 - aryl boronic ester 8
 - aryl ether boronates 5
 - aryl methyl sulfides 275, 276
 - aryl sulphide 275
 - arylboronic acids to enone 293, 294
 - asymmetric allylboration of, aldehydes 281
 - asymmetric catalysis 270, 295, 298, 300, 304
 - asymmetric cyclopropanation of, enals 284
 - asymmetric hydroformylation 292, 293
 - asymmetric Michael reaction 279, 284, 288, 301, 302
 - asymmetric organocatalytic aldol reaction 272, 273
 - asymmetric total synthesis, in continuous flow 298–303
 - asymmetric transfer hydrogenation reaction 277
 - Atazanavir 236, 325
 - automated flow chemistry platforms
 - analytical techniques 33–38
 - future opportunities 38
 - in-line infrared spectroscopy (IR) 35
 - in-line NMR monitoring 34–35
 - in-line Raman spectroscopy 38
 - online HPLC and GC sampling 35–36
 - online mass spectroscopy 37
 - UV/vis spectroscopy 37
 - flexible and modular automated platforms 43–52
 - high-throughput screening platforms 38–39
 - integrated chemistry and bioactivity screening platforms 39–43
 - self-optimization algorithms 52–60
 - automated flow synthesis 90–93
 - automatic synthesis 93
 - automation
 - flexible and modular automated platforms 43–52
 - internet-based software platform 50–51
 - OpenFlowChem 49–50
 - other platforms 51–52
 - reconfigurable system 44–48
 - robotic platform for synthesis 44
 - high-throughput screening platforms 38–39
 - integrated chemistry and bioactivity screening platforms 39–43
- b**
- back pressure regulator (BPR) 36, 172, 176, 180, 249
 - batch carboxylation process 6
 - benzimidazolone derivative 217
 - benzyl trifluoroborate 240
 - biaryl compounds 252
 - bicyclo[1.1.1]pentane (BCP)
 - trifluoroborate salts 23, 24
 - bile acids C3-glucuronides 180
 - bioactive molecules 39, 82, 135, 282
 - bioactivity prediction model 43
 - biphasic flow-reactions 122, 217
 - biphasic reaction mixtures 131
 - black-box optimization 258, 260
 - Boc-deprotection 11, 12
 - Bodroux reaction 70, 71
 - boronate 3–5, 8, 17, 76, 86
 - borylation procedures 5, 6, 252
 - bromination–imination–thermolysis sequence 249
 - bromoarenes 87
 - bromomalonates 284
 - bromomethyl alkoxy intermediate forms 9
 - bromomethyl lithium 7, 9

- Buchwald–Hartwig amination reaction 74
- Buchwald–Hartwig coupling 75, 115, 116, 118, 121
- Buchwald–Hartwig reaction 114, 118
- N*-butyllithium 3, 215
- C**
- carbamate formation 113
- carbamylation reaction 205
- carbazole scaffolds 240
- carbon beads (CBs) 293
- carbonylations 68
- N,N*-carbonyldiimidazole (CDI) 202, 255
- catalyzed enantioselective nitroaldol (Henry) reaction 294
- catalyzed Ritter-type intermediate 252
- catch-and-release approach 135, 137, 163
- Cefotaxime 202–203
- Celite packing material 115
- central composite face-centered (CCF) 57
- chemical transformations 46, 47, 89, 162, 207, 235, 252, 311, 329
- chemoselective amidation 131, 207
- C-heteroatom bonds 70
- chiral alcohols 277, 292, 298, 322
- chiral amines 275, 282
- chiral imidazolidinones 274, 289, 290
- chiral sulfoxides 275
- 2-(chloroethyl)amine hydrochloride 218
- chloroformate reaction 313
- α -chloro ketone precursors 236
- 4-(chloromethyl)benzoic acid 107, 108
- 4-(chloromethyl)benzoyl chloride 108
- chloromethyl epoxide 9
- α -chloromethyl ketones 17
- cholinesterase inhibitor
Donepezil 219–221
- chromosomal translocation 105
- chronic myeloid leukemia (CML) 105, 144
- Claisen–Schmidt condensation reaction 59, 60
- closed-loop multienzymatic platform 296
- closed-loop optimizations 45
- C–N bond formation 123, 125, 128, 130–134, 207
- C–N cross-coupling reactions 121
- co-eluting carbamate 112
- coil reactor 126, 131, 132, 163, 166, 178, 179, 184, 211, 224, 275, 303
- collectors 164
- combined flow-batch synthesis 182
- concentration-dependent fluorescence assay 190
- continuous flow bioaffinity assay 166, 167
- continuous flow bioaffinity unit 166
- continuous flow catalysis 270, 280
- continuous flow formylations 6
- continuous-flow microfluidic reactor 74
- continuous-flow processing 199–227, 293, 311
- continuous flow protocols 69
- convergent multistep flow synthesis
histone deacetylase inhibitor precursor 252
Linezolid 252–255
- copper reactor 78
- Corey–Chaykovsky epoxidation 207–209
- CORNING Advanced-Flow Reactor flow photoreactor 240, 249, 273
- critical process parameters (CPP) 256
- critical quality attributes (CQA) 256
- cryogenic flow carbonylation 6, 7
- cryogenic flow chemistry 2–10
- cyanation 10
- organolithium chemistry, in flow 3–10
boronate synthesis 3–5
carboxylation 6–7
formylation 5–6
halomethylithium species 7–9
Mannich-type additions 9–10
nucleophilic addition 7

- cryogenic liquid 35
- cryogenic reactions 2
- 1,4-cubanedicarboxylate 22, 23
- current drug discovery toolkit 70
 - heterocyclic synthesis 76–80
 - reactions, for c-heteroatom bond formation 70–75
 - reactions, for C–C bond formation 75–76
- Curtius rearrangement 178
- cyanation 10, 11, 296
- cyanogen bromide (BrCN) 236, 243, 246
- cyanoheteroarenes 87
- 4-cyanophenyl derivative 180
- cyclodextrin (CD) 177, 279
- cyclofluidic closed-loop drug discovery 168
- Cyclofluidic Optimisation Platform (CyclOps™) 42, 183
- (*R*)-cyclohexylglycine compound 186
- cycloisomerization 90
- cyclopropyl boronates 17
- cystic fibrosis transmembrane conductance regulator
 - Ivacaftor 224–225
- d**
- deacylation process 318
- deacylation reactions 318, 319
- deprotonation 3, 5, 7, 249, 256
- design-of-experiments (DoE) 53, 57, 92, 255
 - strategies 255
- diazomethane (CH₂N₂) 17–21, 25, 82, 236, 238
- α-diazocarbonyls 17
- dibromo intermediate 9
- α-dibromoketones 84
- β-dicarbonyl compounds 273, 282
- β-dicarbonyl substrates 274
- dichloromethane (DCM) 7, 8, 109, 110, 112–114, 121, 124, 139, 203, 242, 272
- dichloromethylithium 7–9
 - generation 7–8
- 3,6-dichloropyridazine-4-carboxylic acid 178
- diethyl malonate 246, 300
- diethylformamide (DEF) 15
- 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) 182, 183
- diisopropylethylamine (DIPEA) 109, 185, 186, 223
- diluted ammonia solution 242
- dilution module 142
- 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium tetrafluoroborate (DMT-MM) 187
- N,N*-dimethylactamide (DMAc) 242
- dimethylformamide (DMF) 5, 15, 107, 109–114, 124, 147, 180, 202, 204, 212, 225
- N,N*-dimethylformamide 5, 107, 202
 - solvent system 202
- dimethyl malonate 301
- N,N'*-dimethyloctanamide (DMO) 121–123, 126, 128
- 2-[(2,4-dimethylphenyl)sulfanyl]aniline 218
- 1,4 dioxane 202
- dipeptidyl peptidase 4 (DPP4) inhibitors 42, 43, 94, 184, 185
- diphenylphosphoryl azide (DPPA) 178
- displacement reaction 110–112, 114, 126
- diversely functionalized alkynes 173
- diversity-oriented synthesis (DOS) 70, 82, 169, 170
- drug discovery 42, 60, 67–95, 103, 104, 107, 140, 145, 159–161, 168–170, 182, 191, 256, 260, 262, 269, 272, 286
- drug discovery toolkit 70–90
 - combining flow, with emerging technologies 85–90
 - electrochemistry 88–90

- photochemistry 85–88
 - handling hazardous and unstable reagents 80–85
 - dual photoredox-nickel catalysis 87
 - dynamic combinatorial chemistry (DCC) 39, 40, 190
 - dynamic combinatorial libraries (DCLs) 40, 189
- e**
- Efaproxiral (enhancement of radiation therapy) 70
 - Eflornithine 246–249
 - electronic circular dichroism (ECD) 176
 - electron-rich cinnamaldehydes 284
 - elitist genetic algorithm 59
 - enantioenriched pyranonaphthoquinones 285, 286
 - enantioselective biocatalysis, in flow 295–298
 - enantioselective catalysis 269–280
 - enantioselective hydrocyanation reaction 296
 - enantioselective Rhodium-Catalyzed Hydrogenation 291, 292
 - end-to-end autonomous discovery platforms 181–190
 - enzymatic segmented flow approach 299
 - epichlorohydrin 202, 240, 252
 - (+)-epichlorohydrin 202, 252
 - epimer impurity 314, 315
 - eribulin mesylate intermediates 7
 - erythro-alcohol 277
 - 1-ethyl-4-isobutylbenzene 227
 - ethyl octadecanoate 190
 - ethyl palmitate 190
 - exothermic phosgenation reaction 312
- f**
- Farnesoid X Receptor (FXR) 181, 182
 - female hypoactive sexual desire disorder (HSDD) 217
 - Fetizon's reagent 180, 181
 - flash chemistry 3, 5, 83, 85, 252, 253
 - flow-based Buchwald–Hartwig coupling 116
 - flow-based medicinal chemistry
 - automation, remote control and software application 168–169
 - bioassays for, in-line compound screening 164–168
 - continuous flow synthesis machines 162–164
 - PAT 164, 165
 - flow-based nitrile hydration 133
 - flow-based techniques 104
 - flow borylation 5
 - flow chemistry 1–26, 33–60, 67–95, 103–154, 160–162, 165, 175, 177, 204, 207, 256, 280, 300, 326, 329
 - flow chemistry in, medicinal chemistry
 - closed-loop discovery 140–144
 - identification of, Novel Bcr-Abl kinase inhibitors 144–153
 - Imatinib
 - Buchwald flow synthesis of 121–128
 - discovery of 105–106
 - hybrid approach 135–140
 - Jamison flow synthesis of 128–135
 - Ley flow synthesis of 106–121
 - flow-enabled syntheses 7
 - flow-mediated Overman rearrangement 11
 - flow photochemical reactor 21–23
 - flow photochemistry-enabled rearrangements 22
 - flow reactor 2, 10, 11, 19, 35, 37, 44, 50, 57, 72, 76, 90, 116, 161, 162, 203, 210–212, 217, 218, 225, 233, 234, 249, 260, 263, 273, 277, 279, 292, 311–318, 326–329
 - equipment 2
 - flow strategies, for building bioactive compound libraries 169–181

flow strategies, for building bioactive compound libraries (*contd.*)
 click chemistry 169–174
 linear and multistep synthesis 177–181
 MCR 174–177
 flow synthesizer 162, 163, 176, 189
 flow trifluoromethylation 24
 fluconazole 9, 207–210
 fluorescence resonance energy transfer (FRET) assay 166, 167
 fluorescent tracer ligand (DAHBA) 166
p-fluorocinnamaldehyde 301
 fluoroform 246
 formylation procedures 6
 Fourier transform infrared (FTIR) 69, 163
 free-flowing suspension 117
 Friedel–Craft’s acylation 225
 and alkylation 207–208
 frontal affinity chromatography (FAC) 178, 179
 functionalized cyclobutylzinc reagents 90
N-fused-trifluoromethylated heterocycles 90

g

gas chromatography (GC) 45, 163, 163, 256
 gaseous reagents 68, 86, 237
 gas-liquid phase reaction 210
 gas-liquid separator 21
 gastrointestinal stromal tumors (GIST) 105
 Gaussian processes (GPs) 59
 generators of, small molecule reagents 234–237, 239
 GlaxoSmithKline (GSK) 69, 70, 141, 182, 211
N-glycosidation of, isomer 215, 216
 “go-no-go” decisions 68
 G-protein coupled estrogen receptor (GPER) 175–177
 Grignard reagents 82, 83, 88

h

Hajos–Parrish ketone 288
 halomethylithium species 7–9
 hazardous chemical waste 73
 Hemetsberger–Knittel indole formation 11, 14
 heteroaromatic compounds 90, 123
 heteroaromatic enals 284
 heterocyclic synthesis 76–80
 heterogeneous enantioselective catalysis, in flow 280–295
 supported organocatalysts
 enantioselective α -amination 282
 enantioselective allylation, of aldehydes 281
 enantioselective arylation, of aldehydes 282–283
 enantioselective cyclopropanation 283–284
 enantioselective Michael reaction 284–286, 287
 enantioselective Tandem Michael addition/cyclization reactions 286–288
 reduction of, imines 288–290
 supported organometallic catalysts
 enantioselective 1,4-addition to enone 293–294
 enantioselective hydroformylation 291–293
 enantioselective hydrogenation 289–291, 292
 enantioselective nitroaldol reaction 294–295
 hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU) 186
 high performance liquid chromatography (HPLC) 45, 94, 141, 163, 182, 218, 246, 256, 279, 321
 high-temperature flow chemistry 10–14
 high-throughput experimentation (HTE) 38, 39, 93
 high-throughput screening (HTS) 38–39, 67, 151, 160, 174, 183

- histone deacetylase (HDAC) inhibitor 252, 253
- hit identification (Hit Id.) 67, 159, 171, 175, 188
- HIV protease inhibitors 236, 238
- Hoffman-La Roche platform 94
- homogeneous diffusion 39
- homogeneous enantioselective catalysis 270–280
- homogeneous enantioselective organocatalysis 271–275
- enantioselective aldol reaction 272, 273
- enantioselective imine reduction 274–275
- enantioselective michael addition 271–272
- enantioselective photooxygenation 272–274
- organometallic enantioselective catalysis
- enantioselective epoxidation 276–277
- enantioselective hydrogenation 277–279
- enantioselective Michael addition 279–280
- enantioselective sulfoxidation 275–276
- homogeneous enantioselective organocatalysis
- enantioselective aldol reaction 272, 273
- enantioselective imine reduction 274–275
- enantioselective michael addition 271–272
- enantioselective photooxygenation 272–274
- Horner–Wadsworth–Emmons (HWE) olefination 46
- human immunodeficiency virus (HIV) protease substrate-1 74, 166, 167, 180, 181, 210, 211, 215, 236, 238, 325
- “hybrid” flow/batch approach 104
- hydrogenations 68, 235
- hydrolysis yielding (*R*)-Naproxen 298
- hydroxychloroquine (HCQ) 221, 222, 243, 244
- α -hydroxy- β -dicarbonyl compounds 273, 282
- 5-hydroxyisoxazolidines 286
- i**
- Imatinib
- Buchwald flow synthesis of 121–128
- discovery of 105–106
- hybrid approach 135–140
- Jamison flow synthesis of 128–135
- Ley flow synthesis of 106–121
- immobilized human serum albumin (HSA) 178
- in-line analysis 34, 141, 164, 255, 256, 260
- in-line infrared spectroscopy (IR) 35
- in-line liquid-liquid separator 176, 225, 286
- in-line NMR monitoring 34–35
- in-line Raman spectroscopy 38
- in-line spectroscopy 163
- in situ* reagent generation 235
- in situ* use of, hazardous reagents 14–20
- diazomethane 17–20
- phosgene 16–170
- Vilsmeier reagent 15–16
- inhalational anthrax 200
- inner gas-permeable tube 17
- integrated flow synthesis 118–119
- integrated platforms 42, 93–94, 145, 183
- Internet protocols (TCP/IP) 51
- intramolecular nucleophilic substitution 74
- ionic liquid (IL)-based flow strategy 296
- isopropoxycarboxylate 5
- isopropylmagnesium chloride 71
- Isothermal Hierarchical DNA Construction (IHDC) software 188

k

ketothiazoles 180

l

β -lactamase inhibitor 313
lactate dehydrogenase (LDH) 174
late lead optimization 67, 68
Latin hypercube sampling (LHS) 54, 59
lead optimization 67, 68, 142, 144, 160, 161, 191
learning machines (LM) 160
10- μ L glass microreactor 271
ligand efficiency (LE) 175
light emitting diode (LED) 45, 166
light-induced Kumada coupling 88
linear and multistep synthesis 177–181
linear multistep flow synthesis 243–252
 Eflornithin 246–249
 ketamine 249–250
 Lesinurad 251
 Valsartan precursor 246, 247
lipophilic ligand efficiency (LLE) 175
liquid chromatography (LC) 34, 94, 109, 141, 163, 166, 182, 218, 246, 256, 279, 321
liquid-liquid membrane separations 163
liquid-liquid separator 45, 176, 225, 281, 284, 286
lithiation-borylation sequences 5
lithium bis(trimethylsilyl)amide 71
loop injection system 180

m

Mannich-Type additions 9–10
mass spectrometry (MS) 39, 69, 94, 109, 163, 205
merging flow chemistry and drug discovery 69–70
metal-free Michael addition 272
metal-organic frameworks (MOFs) 280
metalation of, dibromomethane 84
methanolic ammonia 110
2,4-methanopyrrolidine intermediate 22
methanopyrrolidine substrates 22

methylation using methyl triflate 226
2-methyl-3-butyn-2-ol (MBY) 49, 50
N-methyliminodiacetic acid ester (MIDA) 76
N-methylpiperazine 108–112, 114, 118, 126
N-methylpiperazine reagent 111
N-methyl-pyrrolidone (NMP) 184, 207, 209, 218
16 microliter droplets 54
micro-reactions 69, 256
microchip reactor 166, 174, 182, 190
microflow system 39, 40
microfluidic circuit 170
microfluidic continuous-flow injection titration assay (CFITA) 166–168
microfluidic multiplexer 170, 171
microfluidic systems 39, 173, 277
microliter chaotic mixer 170
microscale flow synthesizer 189
microwave irradiation 89, 114, 163
model-based design-of-experiments (MBD_{oE}) 53, 54
modular micro reaction system (MMRS) 256
moisture-regulated incubator 170
monolithic macroporous column 271
multi-objective active learning (MOAL) algorithm 54, 59, 281
multi-step continuous flow diazomethane chemistry 17–18
multicomponent reactions (MCRs) 174–177, 233
multiple injections in a single experimental run (MISER) 36
multiple monitoring techniques 34
multistep flow synthesis 177, 234, 243–262, 298
multistep organolithium transformation 34
multistep synthesis 52, 106, 162, 177–181, 207, 233–263, 301
multiwalled carbon nanotubes (MWCNT) 293

n

nanomolar potency 185
 naproxen butyl ester 298
 naproxen esters 298
 natural product synthesis 40
 n-butyllithium 3, 215
 N-dimensional optimization 52
 Negishi coupling 83, 88, 92
 Nelder–Mead Simplex algorithm 53, 54
 Nevirapine 74, 180
 new chemical entities (NCEs) 159
 N-formylmorpholine (NFM) 15
 N-heterocycles 56
 nitrillium ion intermediate 202
 γ -nitroaldehyde 303
 nitrosating agent 205
 β -nitrostyrene 271, 272, 279
 β -nitrostyrene reagent 271
 nitrosyl chloride (NOCl) 236
 N-methylimidazole 284
 non-peptide angiotensin II receptor blocker
 Valsartan 223–224
 non-steroidal anti-inflammatory agent
 Ibuprofen 225–227
 non-steroidal anti-inflammatory drugs (NSAIDs) 44, 298
 novel Abl kinase inhibitors 183
 Novel Process Windows (NPW) 233
 nuclear magnetic resonance (NMR) 34, 35, 67, 69, 138, 163, 256, 258
 nucleobase syringe solution 215
 nucleophilic addition 7, 300
 nucleophilic aromatic substitution (S_NAr) 46, 58, 73, 260
 nucleophilic substitution reaction 202

o

off-line analysis 34
 on-line analysis 34
 on-line mass spectroscopy 37
 one-pot Schotten–Baumann reaction 179
 OpenFlowChem 49–50, 168, 169
 organic/aqueous components 121

organocatalysis 271–275, 288
 organolithium 3–10, 34, 256
 organolithium chemistry, in flow
 boronate synthesis 5
 organomagnesium heterocycles 85
 organometallic enantioselective catalysis
 enantioselective epoxidation 276–277
 enantioselective hydrogenation 277–279
 enantioselective Michael addition 279–280
 enantioselective sulfoxidation 275–276
 organometallic reagents 71, 236
 osteoarthritis 225
 oxidative dimerization 40, 258
 oxo-tethered ruthenium
 complex-catalyzed dynamic kinetic resolution 277
 oxymrophone 242
 ozonolysis reaction 225

p

Paal–Knorr reaction 46
 packed-bed reactor 44, 45, 122, 124, 126, 128, 130, 133, 202, 205, 211, 255, 269, 271, 278, 281, 282, 284, 286, 289, 293, 298, 299, 303, 317–326, 329
 parallel synthesis 69, 151, 171
 paroxetine 301, 302
 Pd-catalyzed *N*-demethylation 243
 Pd-mediated couplings 104, 114
 Pd(II)-precatalyst complex 117
 PEEK coiled microreactor 276
 peptide synthesis 70, 72
 perfluoroalkoxyalkane (PFA) tube reactor 122
 perfluoroalkylation 86
 performic acid generation 303
 (*R*)-phenylglycine derivative 186
 Philadelphia chromosome 105
 phosgene 16, 25, 312–317, 328
 phosphorus oxychloride ($POCl_3$) 15

- photochemical Paternò-Büchi reaction 22, 56
 - photochemistry, on scale 20–26, 45, 69, 85–88, 95, 272
 - photoflow reactions 85
 - photoredox catalysis 58, 87
 - photoredox process 86
 - photoredox transformations 105
 - photoredox/nickel dual catalyzed cross coupling 240
 - Pictet–Spengler reaction 89
 - plausible mechanism 32, 325
 - plug flow reactor (PFR) 292
 - system, for phosgenation reaction establishment and development 314–317
 - feasibility study 313–314
 - polyether ether ketone (PEEK) membrane 223, 224, 276, 278, 279
 - polymer-supported electrophile 109
 - polymer-supported isocyanate 110, 126
 - polystyrene-poly(ethylene glycol) (PS-PEG) 293
 - polytetrafluoroethylen (PTFE) 172, 246, 275
 - precise reaction configuration 129
 - (*S*)-Pregabalin precursor 300
 - process analytical technologies (PAT) 33, 35, 38, 39, 52, 53, 60, 164, 256–258, 263, 304, 311
 - proportional-integral-derivative (PID) control 49
 - protection/deprotection of amines 70
 - protodehalogenated material 115, 118
 - protodehalogenated side-product 115, 117, 118
 - PS-supported
 - cis*-4-hydroxydiphenylprolinol catalyst 301
 - pumping modules 163
 - purification systems 163
- q**
- 4-quinolone-3-carboxylic acid ester 224
- r**
- rapid deprotonation/transmetallation 3
 - rapidly dissipate exotherms 3
 - reactor 163
 - active reactor 2
 - Vapourtec reactor 10, 73
 - reagent generators 236, 237, 239
 - reduced graphene oxide (rGO) 293
 - reductive amination 72
 - catalytic hydrogenation 73
 - supported sodium borohydride 73
 - reductive amination reactions 70, 73, 217
 - reverse-phase chromatography 181, 182
 - Rifampicin 203–205
 - Rimonabant (anti-obesity drug) 70
 - Ritter-reaction 202
 - (*S*)-Rolipram 298–300
 - Ruthenium hydrogenation catalyst 277
- s**
- β -secretase (BACE1) 94, 186, 187
 - selectivity factor (SF) 172
 - self-optimization strategy 57
 - separators 45, 163
 - serotonin modulators and stimulators
 - Flibanserin 217–218
 - Melitracen HCl 218–219
 - Vortioxetine 218
 - Seven-step continuous flow synthesis 201
 - Shono oxidation 89
 - Sigma-Aldrich microreactor 71
 - simple and practical packed-bed reactor system 317
 - deacylation reaction, with
 - anion-exchange resin 318–322
 - commercial production 328
 - feasibility study 318–319
 - pharmaceutical intermediates 319–322
 - reductive amination, with biocatalyst 322–326, 328
 - simplex algorithm 51, 53–56
 - single-step flow reactor 234

- size-exclusion chromatography (SEC)-MS 39, 189
- size-independent ligand efficiency (SILE) 175
- slow-diffusion 114
- small-scale flow system 278
- SNOBFIT algorithm 50, 56–58, 260
- solifenacin 314, 315, 317, 329
- solvent-resistant nanofiltration (SRNF) 278
- Sonogashira reaction 59, 76, 90
- space velocity (SV) 318
- spiro-oxaziridines 21
- stainless-steel reactor 131, 134, 178
- stereocontrolled synthesis 284
- stereogenic C–C bond formation 294
- stereoselective/chemoselective reactions 322
- Stevens' procedure 249
- streamline chemical synthesis 161
- structure-activity relationships (SAR) 42, 60, 68, 94, 144, 150, 159, 173, 183, 185
- structure-properties relationships (SPR) 68, 122
- sulfonyl chlorides 179, 182, 185, 186
- supercritical carbon dioxide 55
- supported ionic liquid phase (SILP) catalyst 291
- Suzuki-Miyaura cross-coupling reactions 39, 53, 70
- Suzuki-Miyaura reaction 38
- synthesize-relevant drug-like compounds 103
- t**
- target molecule (TM) 104, 145, 227, 252
- T-cell tyrosine phosphatase (TCPTP) 182, 183
- telescope reactions 9
- telescoped process 301, 303
- temperature extremes 2–14, 25
- temperature gradients 2
- ten-gram-scale synthesis 294
- tetrahydroisoquinoline intermediate 9
- 5-thiazol-2-yl 3,4-dihydropyrimidin-2(1*H*)-ones (DHPMs) 180
- Thomson-Sampling Efficient Multi-objective Optimization (TSEMO) 59, 60
- three-dimensional (3D) unique binding sites 169
- three-step continuous flow synthesis 226
- T4 lysozyme 298
- total residence time 5, 202, 207, 209, 212, 223, 224, 227, 251, 255, 285
- T-piece connector 118
- T-piece mixer 313
- transmetalation 3, 5
- 1,2,3-triazolyl-4,5-didehydro-5,6-dideoxy-L-ascorbic acid 173
- tricyclic active pharmaceutical intermediate 218
- triethylamine (TEA) 75, 90, 203
- trifluoroborate salt 24, 87
- trifluoromethylating agent 23, 86
- trifluoromethylation 23, 24, 86
- trimethylaluminium (AlMe₃) 70
- triphosgene 16, 312, 313, 316, 317, 328
- triphosgene-mediated flow system 312
- trisubstituted cyclic enones 276
- tube-in-tube diazomethane reactor 20
- tube-in-tube reactor 17, 19, 82, 163, 236
- turnover numbers (TONs) 269
- two-step flow synthesis 237, 240
- amino alcohol APIs, from glycerol 240–242
- clausine C derivatives 240, 241
- hydroxychloroquine 243, 244
- oxymorphone 242–243, 245
- u**
- ultra performance liquid chromatography (UPLC) 36, 38, 256
- ultraviolet-visible (UV-vis) 163
- undesirable diketopiperazines 72

- United States' Food and Drug Administration (FDA) 199, 251, 256, 311
- α,β -unsaturated aldehydes 283, 286, 303
- urate anion exchange transporter 1 (URAT1) inhibitor 251
- urokinase-type plasminogen activator (uPA) 185
- US Food and Drug Administration (FDA) 67, 199, 251, 256, 311
- UV/vis spectroscopy 37
- V**
- Valsartan precursor 223, 224, 246, 247
- vapor-liquid mass transfer rates 292
- Vapourtec R2S-series flow reactor 90
- Vapourtec reactor 10, 73
- Vilsmeier reagent 15–16, 25
- 2-vinyl-6-methoxynaphthalene 292
- W**
- water-electrolysis hydrogen generator 235
- X**
- X-ray diffraction (XRD) 68, 163, 183
- Z**
- Zinc insertion-Negishi coupling 83, 92

